Nature Cancer · Published 2026-05-12 · DOI 10.1038/s43018-026-01163-w
Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Ryan C. Gimple, Alexandra J. Livingstone, Kaleigh F. Roberts, Omar H. Butt, S. Peter Goedegebuure, Michael D. McLellan, Gue Su Chang, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Sophia A. Paxton, Srestha Chattopadhyay, Neil Cooch, Alfredo Perales-Puchalt, Konstantina Stavroulaki, Sarah Rochestie, Joann Peters, Beth Junker, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert H. Kim, Jon T. Willie, Gregory J. Zipfel, Joshua L. Dowling, Christopher A. Miller, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine E. Miller, Elaine R. Mardis, Niranjan Y. Sardesai, Gavin P. Dunn, Tanner M. Johanns
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Garfinkle, E., Perales-Linares, R., Gimple, R., et al. (2026). Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial. Nature Cancer. https://doi.org/10.1038/s43018-026-01163-w